tbuckley/cabot-search huggingface dataset:
AB0901 The Role of Alcohol Related Facial Flushing Response on The Relationship between Risk of Hyperuricemia and Alcohol Consumption
Authors: E. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Alcohol is known to be associated with the occurrence of hyperuricemia. Facial flushing responses to drinking appears to be due to the intelerance to alcohol. This study assessed the role of the facial flushing response in the relationship between alcohol consumption and hyperuricemia. <h3>Objectives</h3> The subjects were 845 Korean adult males (463 non-flushers, 382 flushers) who had undergone a health check-up at an university hospital. <h3>Methods</h3> Data were collected from the subjects9 medical records. After Adjusted for high density lipoprotein cholesterol, hypertension, diabetes, log-transformed triglyceride, log-transformed estimated glomerular filtration rate, body mass index, a logistic regression analysis was used to calculate the risk of hyperuricemia with drinks per week as compared with non-drinkers of each group. <h3>Results</h3> In non-flushing group, the risk of hypeuricemia was significantly increased when non-flushers consumed more than 8 drinks per week (odds ratio [OR], 2.61; 95% confidence interval [CI] 1.05–6.51). In contrast, a higher risk of hyperuricemia was associated with flushers who consumed even &lt;2 drinks (OR, 3.33; 95% CI, 1.01–10.98) per week. <h3>Conclusions</h3> These findings suggest that the amount of drinking associated with the risk of hyperuricemia in flushers was lower than in non-flushers. <h3>References</h3> Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312–24. Jung JG, Kim JS, Yoon SJ, Oh MK. Relationships among alcohol consumption, facial flushing response, and metabolic syndrome in healthy men. Ann Epidemiol 2012;22:480–6. <h3>Disclosure of Interest</h3> None declared
Disregulation of <i>mir-550</i> and <i>let-7e</i> in intestinal high-risk localized GIST: A GEIS study.
Authors: Jose Antonio Lopez-Guerrero, Antonio Fernandez-Serra, Silvia Calabuig, Dolors Sanchez-Izquierdo, Antonia Obrador, Jose Duran, Luis Rubio Martinez, Regina Alemany, Javier Martin Broto
Journal: Journal of Clinical Oncology (2014)

10514 Background: Risk classification of gastrointestinal stromal tumors (GISTs) is critical owing to adjuvant systemic treatments with tyrosine kinase inhibitors (TKI). Tumor size, mitotic count, location or tumor rupture are used to assess patient prognosis after surgical resection and have been validated for GIST risk stratification. miRNAs have been involved in the pathogenesis and progression of most tumors. The purpose of this study is to characterize and to validate differentially expressed miRNAs from a series of recurrent and non-recurrent intestinal hig-risk GIST patients. Methods: RNA from 14 formalin-fixed and paraffin-embedded (FFPE) intestinal high-risk GIST was extracted and analyzed using the GeneChip miRNA 3.0 Array (Affymetrix). The median of tumor size and mitotic count was 11cm (range: 5-25) and 12.5 (range: 0-113 x50 HPF) respectively. Recurrence [median follow-up: 84 months (1-180)] was reported in 8 patients. Normalization and statistical analysis were performed with Partek Genomic Suite 6.6 software and technical validation was conducted using qRT-PCR. Results: A set of 33 miRNAs was significantly deregulated (p=0.05; FC=2) comparing relapsed and non-relapsed patients. Principal Components Analysis divided the patients into two groups: one that comprised the three largest GIST from relapsed patients, and another group with the other cases. We identified 134 miRNAs as differentially expressed between these two groups (p<0.0001; FC=20). The most significantly downregulated miRNAs were let-7e (FC=-1163,99, p<0.0001), miR-17 (FC= -861,879, p<0.0001), miR-195 (FC= -785,334, p<0.0001), miR-143 (FC= -627,526, p<0.0001) and up regulated miR-550 (FC= 204.173, p<0.0001) and miR-1184 (FC= 184.493, p<0.0001). miR-550 and let-7e were selected for technical validation by qRT-PCR confirming the up- (FC=18.0421) and down-regulation respectively (FC=0.6294). Conclusions: Most of the identified miRNAs are involved in cell cycle control and proliferation. We validated the deregulation of miR-550 and let-7e in large intestinal high-risk GISTs. Further studies in independent series of localized GIST with long follow-up are needed in order to demonstrate the prognostic potential of these miRNAs.
PTH-026 Pre-Operative Endoscopic Management of Biliary Obstruction in Pancreatic Cancer: Are Esge Guidelines Relevant and Achievable In The UK?
Authors: J Chalmers, M James, T Archer, D Gomez
Journal: Gut (2016)

<h3>Introduction</h3> The risks of routine preoperative biliary drainage in pancreatic cancer patients without cholangitis and bilirubin &lt;250μmol/L are established. However, access to early resection without prior biliary stenting is challenging in most UK hepatobiliary (HPB) centres. We evaluated adherence to the European Society of Gastrointestinal Endoscopy guidelines (ESGE 2012) and reviewed clinical and stent outcomes in patients referred through the East Midlands Cancer Network. <h3>Methods</h3> Patients with a diagnosis of pancreatic cancer during 2014 were identified and cross-referenced with our HPB surgical database. We examined patient demographics, diagnostic modality, tumour site and type, whether pre-operative drainage was performed with endoscopic retrograde cholangio-pancreatography (ERCP) or percutaneous trans-hepatic cholangiography (PTC) and stent choice. Clinical outcomes included ERCP and surgical technical success as well as re-intervention rates. <h3>Results</h3> 135 pancreatic cancer cases (70 men; mean age 69±8 years, 65 women; mean age 72±7 years) were identified. Pathological diagnosis from EUS-FNA (n = 42), EUS-FNB (n = 34) or brush cytology (n = 24) was adenocarcinoma (n = 95), adenosqamous carcinoma (n = 2), mucinous adenocarcinoma (n = 2), neuroendocrine tumour (NETs; n = 9), squamous carcinoma (n = 2) and 25 radiological diagnosis alone. 50/135 (37%) patients underwent ERCP with technical success in 29/50 (58%): 14 plastic stents; 10 fr (n = 10), 7 fr (n = 4); and 15 self-expanding metal stents (SEMS); 10 mm fc-SEMS; 4 cm (n = 2), 6 cm (n = 2), 8 cm (n = 2); 10 mm uc-SEMS; 4 cm (n = 3), 6 cm (n = 5) were inserted. ERCP failure was due to either unsuccessful CBD cannulation and stenting (15/21; 71%) or duodenal obstruction (6/21; 29%) and 16/21 (76%) of these had PTC, were resected 2/21 (9%) or palliated 3/21 (14%). Re-intervention following ERCP stenting was required in 8/29 (28%): plastic stents 6/8 (75%) obstruction/cholangitis, SEMS 2/8 (25%) distal migration. 10/15 (67%) with SEMS inserted died &lt;4 months after ERCP. 27/135 (20%) cases underwent surgery: complete resection 10/27 (R<sub>0</sub>; 37%), incomplete resection 7/27 (R<sub>1</sub>; 26%), palliative bypass 7/27 (26%) after a mean delay of 26 d (adenocarcinoma) and 90 d (NETs). 3/27 (11%) developed disease recurrence. In patients with biliary obstruction (9/27 who underwent surgery), 5/9 (55%) had surgical resection without attempted pre-operative drainage, with mean bilirubin 144μmol/L. <h3>Conclusion</h3> Following diagnosis of pancreatic cancer, few patients had surgical resection without prior drainage and overall &lt;10% achieved cure. Success in ERCP biliary drainage should be improved and EUS-guided biliary access explored. Although patency rates are higher with SEMS, a high proportion died &lt;4 m, suggesting better case selection for SEMS is required. <h3>Disclosure of Interest</h3> None Declared
PWE-123 Technical Factors Predict Delayed Bleeding after Endoscopic Mucosal Resection for Complex Non-Pedunculated Colorectal Polyps
Authors: ZPP Tsiamoulos, T Elliott, S Thomas-Gibson, N Suzuki, A Hart, P Bassett, BP Saunders
Journal: Gut (2016)

<h3>Introduction</h3> Delayed bleeding is the most common severe adverse event after p-Endoscopic Mucosal Resection (p-EMR) but factors that may predict delayed bleeding are not well-defined. <h3>Methods</h3> Data were analysed from a prospective single centre observational cohort study of patients with complex NPCPs ≥20 mm who underwent p-EMR between January 2010 and August 2012. Patient, polyp, and procedure-related data were collected. Four post p-EMR resection defect factors were evaluated for interobserver agreement and included in risk analysis. A telephone interview was conducted with patients 14 days post p-EMR. Delayed bleeding severity was reported in accordance with guidelines. Predictors of bleeding were identified by univariable and multivariable analyses. <h3>Results</h3> Delayed bleeding requiring hospitalisation occurred in 22 of 330 (6.7%) patients. Eleven patients required blood transfusion; of these 4 underwent urgent colonoscopy, 1 underwent radiological embolisation and 1 required surgery to achieve haemostasis. Interobserver agreement for identification of the 4 post p-EMR resection defect factors was moderate (kappa &gt;0.5 for each). Predictors of delayed bleeding on multivariable analysis were a previous EMR attempt (odds ratio = 3.13, <i>P</i> = 0.05) and visible muscle fibres in the post p-EMR resection defect (OR 3.64, <i>P</i> = 0.03). Factors not predictive on multivariable analysis included patient age, ASA class, aspirin use, polyp site, polyp size or APC use. <h3>Conclusion</h3> Visible muscle fibres in the p-EMR resection defect and a previous failed p-EMR attempt are predictors of delayed bleeding after p-EMR. These findings emphasise the importance of technical factors in ensuring good outcomes after p-EMR for complex NPCPs. <h3>Disclosure of Interest</h3> None Declared
SECONDARY GASTROINTESTINAL MALIGNANCIES IN CHILDHOOD CANCER SURVIVORS: A COHORT STUDY
Authors: Tara O. Henderson, Kevin C. Oeffinger, John Whitton, Wendy Leisenring, Joseph Neglia, Anna Meadows, Catherine Crotty, David T. Rubin, Lisa Diller, Peter Inskip, Susan A. Smith, Marilyn Stovall, Louis S. Constine, Sue Hammond, Greg T. Armstrong, Leslie L. Robison, Paul C. Nathan
Journal: Annals of Internal Medicine (2012)

Background
Childhood cancer survivors develop gastrointestinal malignancies more frequently and at a younger age than the general population, but risk factors for their development have not been well characterized.
An injectable shear-thinning biomaterial for endovascular embolization
Authors: Reginald K. Avery, Hassan Albadawi, Mohsen Akbari, Yu Shrike Zhang, Michael J. Duggan, Dushyant V. Sahani, Bradley D. Olsen, Ali Khademhosseini, Rahmi Oklu
Journal: Science Translational Medicine (2016)

An engineered shear-thinning biomaterial is used as an embolic agent for vascular occlusion as treatment for bleeding.
A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.
Authors: Jorge Cortes, Guillermo Garcia-Manero, Susan O’Brien, Ingrid Hernandez, Wayne Rackoff, Stefan Faderl, Deborah Thomas, Alessandra Ferrajoli, Moshe Talpaz, Hagop Kantarjian
Journal: Blood (2004)
Umbilical Cord Blood Transplantation after Reduced-Intensity Conditioning for Adults: The Report from Japan Cord Blood Bank Network.
Authors: Naofumi Matsuno, Shuichi Taniguchi, Satoshi Takahashi, Shunro Kai, Yasuji Kozai, Hisashi Sakamaki, Tokiko Nagamura, Minoko Takanashi, Shunichi Kato
Journal: Blood (2007)
Impact of HLA Haplotype Matching On Engraftment in Reduced Intensity Cord Blood Transplantation.
Authors: Kazuya Ishiwata, Hikari Ota, Aya Nishida, Masanori Tsuji, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Koji Izutsu, Shigeyoshi Makino, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2012)
AB0212 Contribution of The Subjective Components of The Disease Activity Score To The Response To Treatment in Rheumatoid Arthritis
Authors: K.M. Son, S.Y. Lee, H.S. Lee, Y.I. Seo, H.A. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In recently, with development of biologic agents, RA patients increased the change of reaching remission. But some patients with normalization of inflammatory sign didn9t reach to clinical remission state after optimization of treatment. <h3>Objectives</h3> This study was performed to investigate the contribution of the more subjective versus the objective component of the DAS28 to response to treatment in RA patient. The secondary aim was to examine the factors associated with 6 month change in pain and EULAR response. <h3>Methods</h3> The DAS28-P was calculated (Subjective components of DAS28 relative to the total DAS28: DAS28-P=0.56*sqrt(TJC28) + 0.014*(VAS-GH)/0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.78 In(ESR) + 0.014*(VAS-GH)). From September 2011 to 2013, 462 new patients were included in this study. EULAR response was assessed after 6month of treatment. <h3>Results</h3> The mean age of the included patient was 54 years, and 79% were female. The mean DAS28 at baseline was 4.91±1.07 (range 3.21–8.56) and that at after 6 months of treatment was 3.29±1.28 (range 0.49–8.47). Good responders according to the EULAR criteria were 180 (38.9%), moderate responders 150 (32.4%) and none responders 96 (22.5%). The change of DAS28-P score at baseline and 6 month was significant only for good responders (0.43±0.11 versus 0.3±0.25, p&lt;0.001) and for moderate responders (0.45±0.09 versus 0.41±0.15, p=0.003) but not significant for none responders (0.44±0.13 versus 0.44±0.12, p=0.727). Among those were failed have good response, those who had objective measures (ESR, CRP, and swollen joint) normalized were defined as failure due to subjective measure. Subjects with failure due to subjective measure were less likely to be RF positive and had lower DAS28 after 6month but higher DAS28-P after 6 month.Higher baseline DAS28 score was associated with better pain response while DAS28, DAS28-P and baseline characteristics of patients (sex, age, RF) were not related to EULAR response <h3>Conclusions</h3> Our study showed that there are distinct RA patients with high DAS28-P, an index derived from subjective measures, who fails to respond adequately to treatment despite normalization of objective measures. <h3>Disclosure of Interest</h3> None declared
Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.
Authors: Yun Dai, Shuang Chen, Xin-Yan Pei, Viswanathan Ramakrishnan, Michael Wang, Robert Orlowski, Paul Dent, Steven Grant
Journal: Blood (2009)
Efficient Enhancement of Blood-Brain Barrier Permeability Using Acoustic Cluster Therapy (ACT)
Authors: Andreas K.O. Åslund, Sofie Snipstad, Andrew Healey, Svein Kvåle, Sverre H. Torp, Per C. Sontum, Catharina de Lange Davies, Annemieke van Wamel
Journal: Theranostics (2016)

The blood-brain barrier (BBB) is a major obstacle in drug delivery for diseases of the brain, and today there is no standardized route to surpass it. One technique to locally and transiently disrupt the BBB, is focused ultrasound in combination with gas-filled microbubbles. However, the microbubbles used are typically developed for ultrasound imaging, not BBB disruption. Here we describe efficient opening of the BBB using the promising novel Acoustic Cluster Therapy (ACT), that recently has been used in combination with Abraxane® to successfully treat subcutaneous tumors of human prostate adenocarcinoma in mice. ACT is based on the conjugation of microbubbles to liquid oil microdroplets through electrostatic interactions. Upon activation in an ultrasound field, the microdroplet phase transfers to form a larger bubble that transiently lodges in the microvasculature. Further insonation induces volume oscillations of the activated bubble, which in turn induce biomechanical effects that increase the permeability of the BBB. ACT was able to safely and temporarily permeabilize the BBB, using an acoustic power 5-10 times lower than applied for conventional microbubbles, and successfully deliver small and large molecules into the brain.
Cementing an unwanted relationship
Authors: Chia-Hao Chang, Li-Ta Keng, Jen-Chung Ko
Journal: Thorax (2016)

A 93-year-old male with COPD, hypertension and stroke presented to the emergency department with cough and dyspnoea. Two months before this episode, he had suffered a compression fracture and therefore received first and second lumbar vertebroplasty with cement implantation. In the emergency department, his oxygen saturation was 88% while breathing ambient air; his other vital signs were normal. Physical examination revealed crackles over his bilateral lung field.

A laboratory test revealed leucocytosis and a mild elevation of the C reactive protein level. A chest …
The Combination of Fludarabine and Cyclophosphamide Has a Beneficial Effect on the Incidence of Hemolytic Anemia in Chronic Lymphocytic Leukemia. Results from the UK LRF CLL4 Trial.
Authors: Claire E. Dearden, Rachel L. Wade, Monica Else, Sue M. Richards, Don W. Milligan, Terry J. Hamblin, Daniel Catovsky
Journal: Blood (2007)
AB0854 Body Adiposity Measures and Their Association with Low Back Pain: Result from A Prospective Cohort Study
Authors: S.M. Hussain, D.M. Urquhart, Y. Wang, J.E. Shaw, D.J. Magliano, A.E. Wluka, F.M. Cicuttini
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Although obesity is associated with low back pain (LBP) prevalence in adults, the mechanism how obesity causes LBP remained unexplored. Since, our current understanding on how obesity causes other joint pain i.e. pain in hand joints suggest that, there must be additional systemic effect of obesity in the pathogenesis of LBP. Thus, clarifying the role of body composition on the risk of LBP is important as it will help in the understanding of likely pathological mechanisms. <h3>Objectives</h3> To examine the relationship between adiposity measures and LBP intensity and disability in community based population. <h3>Methods</h3> 5,058 participants (44% men) of the Australian Diabetes, Obesity and Lifestyle Study recruited at 1999–2000 were included. Their body mass index (BMI), waist circumference, and waist-to-hip ratio were obtained from direct anthropometric measurements. The fat mass and percentage fat were estimated from bioelectrical impedance analysis. LBP intensity and disability assessed in 2013–2014 using the Chronic Pain Grade Questionnaire. <h3>Results</h3> All the adiposity measures were associated with LBP intensity, independent of fat free mass, for both men and women. The odd ratios (OR) of men for high intensity LBP were BMI OR 1.41 (95% CI 1.17–1.70), waist OR 1.25 (95% CI 1.07–1.46), waist-to-hip ratio OR 1.33 (95% CI 1.03–1.71), percent fat OR 1.45 (95% CI 1.19–1.77), fat mass OR 1.23 (95% CI 1.05–1.44). For women the ORs were - BMI OR 1.39 (95% CI 1.22–1.59), waist OR 1.36 (95% CI 1.22–1.52), waist-to-hip ratio OR 1.49 (95% CI 1.21–1.84), percent fat (10%) OR 1.39 (95% CI 1.22–1.57), fat mass OR 1.27 (95% CI 1.15–1.40). Similarly all adiposity measures were associated with LBP disability. The risk of LBP intensity and disability increased in a linear manner in sex-specific quartiles of all adiposity measures such that the individuals in the highest quartile had the highest risk of developing LBP. <h3>Conclusions</h3> All adiposity measures were significantly associated with LBP intensity and disability. This suggests a role for metabolic mechanisms associated with adiposity contribute to the risk of LBP. The rise in the obesity epidemic throughout the world is likely to increase the burden of LBP, as such understanding the mechanism of action will be important in effective prevention of the disease. <h3>Disclosure of Interest</h3> None declared
In It for the Long Haul: The Cytocompatibility of Aged Graphene Oxide and Its Degradation Products
Authors: Brian D. Holt, Anne M. Arnold, Stefanie A. Sydlik
Journal: Advanced Healthcare Materials (2016)

Synthetic biomaterials are poised to transform medicine; however, current synthetic options have yet to ideally recapitulate the desirable properties of native tissue. Thus, the development of new synthetic biomaterials remains an active challenge. Due to its excellent properties, including electrical conductivity, water dispersibility, and capacity for functionalization, graphene oxide (GO) holds potential for myriads of applications, including biological devices. While many studies have evaluated the compatibility of freshly prepared GO, understanding the compatibility of GO as it ages in an aqueous environment is crucial for its safe implementation in long‐term biological applications. This is a critical disconnect, as GO has been shown to undergo an autodegradation pathway in aqueous conditions, dynamically changing its composition and structure while producing degradation products. Thus, the long‐term cytocompatibility of GO is investigated by “aging” GO over time in water and accelerating aging and decomposition via sonication. While age affects the composition and size of GO, it has no effect on cellular vitality and does not alter subcellular structures or DNA melting. Overall, GO is cytocompatible throughout the process of aging, beginning to demonstrate that GO may be utilized for long‐term in vivo applications such as implanted tissue engineered scaffolds or biosensors.
Novel E-Selectin Antagonist GMI-1271 Decreases Venous Thrombosis without Increased Bleeding Potential in a Mouse Model
Authors: Daniel Durant Myers, Dorian L Culmer, Jose A. Diaz, Angela E. Hawley, Peter K. Henke, Suman L. Sood, Robert E Sigler, Andrea T Obi, John T. Patton, Thomas W. Wakefield, John L. Magnani
Journal: Blood (2012)
Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).
Authors: Xavier Leleu, Evdoxia Hatjiharissi, Aldo M. Roccaro, Anne-Sophie Moreau, Renee Leduc, Marybeth Nelson, Mena Farag, Steven P. Treon, Irene M. Ghobrial
Journal: Blood (2007)
PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro
Authors: Catherine C. Smith, Alexander E Perl, Elisabeth Lasater, Chao Zhang, Grace R Jeschke, Lauren E. Damon, Martin Carroll, Neil P. Shah
Journal: Blood (2011)
Long-Term Pre-Transplant Imatinib Can Improve the Outcome of Non-Myeloablative Stem Cell Transplantation without Increasing the Morbidity in Ph+ Chronic Myeloid Leukemia.
Authors: Dong-Wook Kim, Ki-Seong Eon, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min, Chun-Choo Kim
Journal: Blood (2004)
Red Blood Cell S-Nitrosohemoglobin Deficiency in Pulmonary Arterial Hypertension.
Authors: John R. Pawloski, Timothy J. McMahon, Martin P. Moya, Andrew J. Gow, Yuh-Chin T. Huang, Benjamin J. Luchsinger, Abigail D. Krichman, Thomas M. Bashore, Robert M. Califf, David J. Singel, Claude A. Piantadosi, Victor F. Tapson, Jonathan S. Stamler
Journal: Blood (2004)